Survodutide MASH Data Show Liver Benefit Beyond Weight Loss, Phase 2 Analysis Finds
A post hoc phase 2 analysis presented at The Liver Meeting 2026 reports survodutide improved MASH and fibrosis endpoints across all weight-loss categories, including patients losing under 5%.
Read article →